Raffles Medical (SGX:BSL) reported 1H24 revenue of S$365.7mil (-1.4% y-o-y, 48% of revised FY24F estimates), on par with our expectations. Excluding intersegment revenue, hospital services remained robust (+2% y-o-y), as Raffles Hospitals in China continued to gain traction.
1H24 revenue in line, earnings below.
- Read this at SGinvestors.io -
Raffles Medical's 1H24 PATMI of S$30.6mil (-49% y-o-y, 45% of revised FY24F estimates) however fell short of our expectations on higher-than-expected operating losses of S$6.4mil in 1H24 vs S$1.3mil loss in 1H23 at RHI, with the higher loss ratio consistent with industry trends.
China hospitals a promising growth engine though we remain cognisant of gestational losses.
- Read this at SGinvestors.io -
China’s slowing economic growth and the stronger Singapore dollar may also dampen the demand for high-end healthcare services whilst margins may face some compression due to inflationary pressures.
Nevertheless, we continue to have a long-term positive outlook on Raffles Medical due to the healthcare industry's long-term positive trajectory and the potential for its China hospitals to ramp up as they reach stabilisation and breakeven in the medium term.
Insurance a wild card.
Read more at SGinvestors.io.
Above is an excerpt from a report by DBS Group Research. Clients of DBS may access the full PDF report @ https://www.dbs.com/insightsdirect/.
Use Trust referral code PGKPSWAE to sign up NTUC Link or Trust Link Credit Card or open a Trust Bank Savings Account: ✨Earn up to S$1,000 cashback rewards 🎟!
